94 related articles for article (PubMed ID: 11460477)
21. Reversible cross-linking of alpha 2-plasmin inhibitor to fibrinogen by fibrin-stabilizing factor.
Ichinose A; Aoki N
Biochim Biophys Acta; 1982 Sep; 706(2):158-64. PubMed ID: 6127110
[TBL] [Abstract][Full Text] [Related]
22. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1.
Madison EL; Goldsmith EJ; Gerard RD; Gething MJ; Sambrook JF; Bassel-Duby RS
Proc Natl Acad Sci U S A; 1990 May; 87(9):3530-3. PubMed ID: 2110366
[TBL] [Abstract][Full Text] [Related]
23. The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis.
Robbie LA; Booth NA; Croll AM; Bennett B
Thromb Haemost; 1993 Aug; 70(2):301-6. PubMed ID: 8236139
[TBL] [Abstract][Full Text] [Related]
24. Identification of respective lysine donor and glutamine acceptor sites involved in factor XIIIa-catalyzed fibrin α chain cross-linking.
Wang W
J Biol Chem; 2011 Dec; 286(52):44952-64. PubMed ID: 22030394
[TBL] [Abstract][Full Text] [Related]
25. The mutation in fibrinogen Bicêtre II (gamma Asn308-->Lys) does not affect the binding of t-PA and plasminogen to fibrin.
Grailhe P; Boyer-Neumann C; Haverkate F; Grimbergen J; Larrieu MJ; Anglés-Cano E
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):679-87. PubMed ID: 8292717
[TBL] [Abstract][Full Text] [Related]
26. [Effect of fibrinogen, fibrin and fibrin (ogen) degradation products on the tissue plasminogen activator and plasminogen activator inhibitor-1 expressions of vascular endothelial cells in coculture system].
Cao YJ; Wu YH; Liu CF
Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Jan; 36(1):62-7. PubMed ID: 19099932
[TBL] [Abstract][Full Text] [Related]
27. Fibrin-mediated plasminogen activation.
Nieuwenhuizen W
Ann N Y Acad Sci; 2001; 936():237-46. PubMed ID: 11460481
[TBL] [Abstract][Full Text] [Related]
28. The structure and biological features of fibrinogen and fibrin.
Mosesson MW; Siebenlist KR; Meh DA
Ann N Y Acad Sci; 2001; 936():11-30. PubMed ID: 11460466
[TBL] [Abstract][Full Text] [Related]
29. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
30. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
31. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
Rouy D; Anglés-Cano E
Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of Borrelia burgdorferi-bound fibrinolytic enzymes by alpha2-antiplasmin, PAI-1 and PAI-2.
Perides G; Noring R; Klempner MS
Biochem Biophys Res Commun; 1996 Feb; 219(3):690-5. PubMed ID: 8645243
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains.
Tsurupa G; Medved L
Biochemistry; 2001 Jan; 40(3):801-8. PubMed ID: 11170397
[TBL] [Abstract][Full Text] [Related]
34. Intramolecular crosslinking of monomeric fibrinogen by tissue transglutaminase.
Murthy SN; Wilson J; Guy SL; Lorand L
Proc Natl Acad Sci U S A; 1991 Dec; 88(23):10601-4. PubMed ID: 1683705
[TBL] [Abstract][Full Text] [Related]
35. Why alpha-antiplasmin must be converted to a derivative form for optimal function.
Lee KN; Jackson KW; Christiansen VJ; Lee CS; Chun JG; McKee PA
J Thromb Haemost; 2007 Oct; 5(10):2095-104. PubMed ID: 17883704
[TBL] [Abstract][Full Text] [Related]
36. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
37. Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis.
Weitz JI; Leslie B; Hirsh J; Klement P
J Clin Invest; 1993 Apr; 91(4):1343-50. PubMed ID: 7682569
[TBL] [Abstract][Full Text] [Related]
38. Altered plasma fibrin clot properties in essential thrombocythemia.
Małecki R; Gacka M; Kuliszkiewicz-Janus M; Jakobsche-Policht U; Kwiatkowski J; Adamiec R; Undas A
Platelets; 2016; 27(2):110-6. PubMed ID: 25989112
[TBL] [Abstract][Full Text] [Related]
39. Crosslinking of alpha 2-antiplasmin to fibrin.
Lee KN; Lee CS; Tae WC; Jackson KW; Christiansen VJ; McKee PA
Ann N Y Acad Sci; 2001; 936():335-9. PubMed ID: 11460490
[TBL] [Abstract][Full Text] [Related]
40. [Activation of fibrynolysis in children with chronic B or C hepatitis].
Michalska K; Szaflarska-Popławska A; Dymek G; Kotschy M
Pol Merkur Lekarski; 2004 Oct; 17(100):316-20. PubMed ID: 15690691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
